BRAF and melanoma: To decrease the latency of melanoma appearance, these compounds are often administered in combination with other agents such as UV rays, or used in genetically engineered mice that harbor activating mutations in BRAF and NRAS, two oncogenes frequently mutated in human melanoma [230].